DRUG
Bright Minds Biosciences Inc.·Healthcare
89.14
4.649%(+3.96)
Close PriceLast Updated: — ET
52W L: $23.1852W H: $123.75
DRUG NEWS
defenseworld.net
Mar 28
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Moderate Buy” from Brokerages
Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target
globenewswire.com
Feb 25
Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:
